PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

Abstract

Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) who respond to salvage chemotherapy. However, relapse after ASCT remains a frequent cause of treatment failure, with poor subsequent prognosis. Because cHL is uniquely vulnerable to programmed cell death-1 (PD-1) blockade, PD-1 blockade given as consolidation after ASCT could improve ASCT outcomes. We therefore conducted a multicohort phase 2 study of pembrolizumab in patients with RR cHL after ASCT, hypothesizing that it would improve the progression-free survival (PFS) at 18 months after ASCT (primary end point) from 60% to 80%. Pembrolizumab was administered at 200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge. Thirty patients were treated on this study. The median age was 33 years, and 90% were high-risk by clinical criteria. Seventy-seven percent completed all 8 cycles. Toxicity was manageable, with 30% of patients experiencing at least 1 grade 3 or higher adverse event (AE), and 40% at least 1 grade 2 or higher immune-related AE. Two patients were lost to follow-up in complete remission at 12 months. The PFS at 18 months for the 28 evaluable patients was 82%, meeting the primary end point. The 18-month overall survival was 100%. In conclusion, pembrolizumab was successfully administered as post-ASCT consolidation in patients with RR cHL, and resulted in a promising PFS in a high-risk patient cohort, supporting the testing of this strategy in a randomized trial. This trial was registered at www.clinicaltrials.gov as #NCT02362997.

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes

“…Recent efforts to restore the immune response by antagonizing the inhibitory signals used by tumors have demonstrated promise. For example, blockade of the immune checkpoints PD-1, CTLA-4, and TIGIT has reported remarkable success in AML (19), lymphoma (20), MDS (21), and multiple myeloma (22). Nevertheless, the antitumor effects of TIGIT or PD-1 inhibitors alone are limited, and further studies are urgently required.…”

The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients

“…PD-1/PD-L1 related antitumor therapy had been improving outcomes for all kinds of malignant diseases. [ 7 – 40 , 53 , 54 ] Some of them had been used as the first line choice alone or combined with chemotherapy. [ 7 – 9 , 11 – 14 , 18 , 19 , 21 , 24 , 25 , 30 , 35 , 38 , 39 ] However, as the range of use expanded, the potential exposure to immune-related adverse events associated with these PD-1/PD-L1 inhibitors also increased.…”

Maintenance Strategies After Hematopoietic Cell Transplantation

“…In addition to BV, anti-PD-1 therapies are effective in R/R HL, and their use is increasing. 40 There is growing interest in applying these agents to the post-auto-HCT consolidation and 41 Enrolled patients were not required to be high-risk, however, 90% had ≥ 1 high-risk feature. At 18 months, all patients who received anti-PD-1 maintenance were alive, and 82% remained in complete remission (CR).…”